Pipeline
      

๊ธ€๋กœ๋ฒŒ ์‹ ์•ฝ๊ฐœ๋ฐœ ๊ฟˆ์— ์—ด์ •์ ์œผ๋กœ ๋„์ „ํ•˜๋Š” ์‚ฌ๋žŒ๋“ค์ด ๋งŒ๋“ค์–ด ๊ฐ€๋Š” 
์‹ ์•ฝ ๊ฐœ๋ฐœ ์„ ๋„๊ธฐ์—… ์™€์ด๋””์ƒ๋ช…๊ณผํ•™ ์ž…๋‹ˆ๋‹ค. 
Pipeline

๊ธ€๋กœ๋ฒŒ ์‹ ์•ฝ๊ฐœ๋ฐœ ๊ฟˆ์— ์—ด์ •์ ์œผ๋กœ ๋„์ „ํ•˜๋Š” ์‚ฌ๋žŒ๋“ค์ด ๋งŒ๋“ค์–ด ๊ฐ€๋Š” 
์‹ ์•ฝ ๊ฐœ๋ฐœ ์„ ๋„๊ธฐ์—… ์™€์ด๋””์ƒ๋ช…๊ณผํ•™ ์ž…๋‹ˆ๋‹ค. 
Chemicals

       

Pipeline


Pipeline

Target ID

Indication

Development Stage

Co-Developer

Estimated 

L/O Stage


YD312

c-Kit

Ophthalmology
(DME, DR, AMD)

Phase 2a

-

In Progress


YDC101

c-Kit

Ophthalmology. Oncology

Lead Optimization

SapiensBio

Candidate


YDC103

Αβ, Tau

Alzheimer’s Disease

Lead Optimization

SapiensBio

Candidate


YDC104

Confidential

Alzheimer’s Disease

Hit

ADDI at

Cambridge U. &

SapiensBio

Candidate


YDC105

Confidential

Fibrosis

Lead Optimization to Candidate

SapiensBio

Pre-Clinical


YDB102

Multigene-

Expression

Oncology

Hit

(POC in in-vivo animal model)

-

After POC

In Vivo Test


YDB201

Multi-Targets

Ophthalmology, Oncology

Hit

-

After POC

In Vivo Test



 YDC103 Alzheimer's Disease

๋Œ€๋ถ€๋ถ„์˜ ์•Œ์ธ ํ•˜์ด๋จธ ์น˜๋ฃŒ์ œ๋“ค์€ ์•„๋ฐ€๋กœ์ด๋“œ ๋ฒ ํƒ€ ๋˜๋Š” ํƒ€์šฐ์˜ ์—‰ํ‚ด์˜ ํ˜•์„ฑ์„ ์–ต์ œํ•˜๊ธฐ ์œ„ํ•ด ๊ฐœ๋ฐœ๋˜์—ˆ์ง€๋งŒ, ๊ธฐ์กด์— ํ˜•์„ฑ๋œ ์‘์ง‘์ฒด๋ฅผ ์ œ๊ฑฐํ•˜์ง€ ๋ชปํ•˜๋Š” ๋ฌธ์ œ์ ์ด ์žˆ์—ˆ๋‹ค.
YDC103์€ ๊ธฐ์กด ์น˜๋ฃŒ๋ฐฉ์‹์˜ ๋ฌธ์ œ์ ์€ ์ด๋ฏธ ๋‡Œ์— ํ˜•์„ฑ๋œ ์‘์ง‘์ฒด๋ฅผ ์šฉํ•ด ์‹œํ‚ค๋„๋ก ์„ค๊ณ„๋œ ์ƒˆ๋กœ์šด ํ™”ํ•ฉ๋ฌผ์ด๋‹ค.
๊ทธ๋Ÿฌํ•œ ํšจ๊ณผ๋ฅผ ํ†ตํ•ด, YDC103์€ ์•„๋ฐ€๋กœ์ด๋“œ ๋ฒ ํƒ€ ๋˜๋Š” ํƒ€์šฐ ์‘์ง‘์„ ๋ง‰์„ ๋ฟ ์•„๋‹ˆ๋ผ, ๊ธฐ์กด์— ํ˜•์„ฑ๋œ ์‘์ง‘์ฒด๋ฅผ ์šฉํ•ด ์‹œ์ผœ, ์•„๋ฐ€๋กœ์ด๋“œ ๋ฒ ํƒ€ ๋˜๋Š” ํƒ€์šฐ ์‘์ง‘์œผ๋กœ ๋ถ€ํ„ฐ ๋ฐœ์ƒ๋˜๋Š” ๋…์„ฑ์œผ๋กœ๋ถ€ํ„ฐ ์‹ ๊ฒฝ์„ธํฌ๋ฅผ ๋ณดํ˜ธํ•˜๊ณ , ์ธ์ง€ ๊ธฐ๋Šฅ์„ ํ–ฅ์ƒ์‹œํ‚จ๋‹ค.
YDC103
     Alzheimer’s Disease
๋Œ€๋ถ€๋ถ„์˜ ์•Œ์ธ ํ•˜์ด๋จธ ์น˜๋ฃŒ์ œ๋“ค์€ ์•„๋ฐ€๋กœ์ด๋“œ ๋ฒ ํƒ€ ๋˜๋Š” ํƒ€์šฐ์˜ ์—‰ํ‚ด์˜ ํ˜•์„ฑ์„ ์–ต์ œํ•˜๊ธฐ ์œ„ํ•ด ๊ฐœ๋ฐœ๋˜์—ˆ์ง€๋งŒ, ๊ธฐ์กด์— ํ˜•์„ฑ๋œ ์‘์ง‘์ฒด๋ฅผ ์ œ๊ฑฐํ•˜์ง€ ๋ชปํ•˜๋Š” ๋ฌธ์ œ์ ์ด 
์žˆ์—ˆ๋‹ค. 
YDC103์€ ๊ธฐ์กด ์น˜๋ฃŒ๋ฐฉ์‹์˜ ๋ฌธ์ œ์ ์€ ์ด๋ฏธ ๋‡Œ์— ํ˜•์„ฑ๋œ ์‘์ง‘์ฒด๋ฅผ ์šฉํ•ด ์‹œํ‚ค๋„๋ก ์„ค๊ณ„๋œ ์ƒˆ๋กœ์šด ํ™”ํ•ฉ๋ฌผ์ด๋‹ค. 
๊ทธ๋Ÿฌํ•œ ํšจ๊ณผ๋ฅผ ํ†ตํ•ด, YDC103์€ ์•„๋ฐ€๋กœ์ด๋“œ ๋ฒ ํƒ€ ๋˜๋Š” ํƒ€์šฐ ์‘์ง‘์„ ๋ง‰์„ ๋ฟ ์•„๋‹ˆ๋ผ, ๊ธฐ์กด์— ํ˜•์„ฑ๋œ ์‘์ง‘์ฒด๋ฅผ ์šฉํ•ด ์‹œ์ผœ, ์•„๋ฐ€๋กœ์ด๋“œ ๋ฒ ํƒ€ ๋˜๋Š” ํƒ€์šฐ ์‘์ง‘์œผ๋กœ ๋ถ€ํ„ฐ 
๋ฐœ์ƒ๋˜๋Š” ๋…์„ฑ์œผ๋กœ๋ถ€ํ„ฐ ์‹ ๊ฒฝ์„ธํฌ๋ฅผ ๋ณดํ˜ธํ•˜๊ณ , ์ธ์ง€ ๊ธฐ๋Šฅ์„ ํ–ฅ์ƒ์‹œํ‚จ๋‹ค.

๋ฒ•์ธ๋ช… : ใˆœ์™€์ด๋””์ƒ๋ช…๊ณผํ•™   ๋Œ€ํ‘œ์ž : ์ด์ง„์šฐ

์ฃผ์†Œ : 13207 ๊ฒฝ๊ธฐ๋„ ์„ฑ๋‚จ์‹œ ์ค‘์›๊ตฌ ์‚ฌ๊ธฐ๋ง‰๊ณจ๋กœ 148 (์ƒ๋Œ€์›๋™) ์ค‘์•™์ด๋…ธํ…Œํฌ 909ํ˜ธ

๋ณธ ์‚ฌ์ดํŠธ์˜ ์ฝ˜ํ…์ธ ๋Š” ์ €์ž‘๊ถŒ๋ฒ•์˜ ๋ณดํ˜ธ๋ฅผ ๋ฐ›๋Š”๋ฐ”, ๋ฌด๋‹จ ์ „์žฌ, ๋ณต์‚ฌ, ๋ฐฐํฌ ๋“ฑ์„ ๊ธˆํ•ฉ๋‹ˆ๋‹ค.
Copyright โ“’ 2016-2024 YD Global Life Science Co. Ltd. All Rights Reserved.